{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:38:33Z","timestamp":1770777513105,"version":"3.50.0"},"reference-count":38,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2021,9,1]]},"DOI":"10.1248\/bpb.b21-00232","type":"journal-article","created":{"date-parts":[[2021,8,31]],"date-time":"2021-08-31T22:08:49Z","timestamp":1630447729000},"page":"1210-1219","source":"Crossref","is-referenced-by-count":19,"title":["Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR \u03b1\/\u03b3 Dual Agonist"],"prefix":"10.1248","volume":"44","author":[{"given":"Akihiro","family":"Honda","sequence":"first","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shotaro","family":"Kamata","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chihiro","family":"Satta","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yui","family":"Machida","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kie","family":"Uchii","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuki","family":"Terasawa","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayane","family":"Nemoto","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuji","family":"Oyama","sequence":"additional","affiliation":[{"name":"Faculty of Life and Environmental Sciences, University of Yamanashi"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Health Chemistry, Showa Pharmaceutical University"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Zoete V, Grosdidier A, Michielin O. Peroxisome proliferator-activated receptor structures: ligand specificity, molecular switch and interactions with regulators. <i>Biochim. Biophys. Acta<\/i>, <b>1771<\/b>, 915\u2013925 (2007).","DOI":"10.1016\/j.bbalip.2007.01.007"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Lefebvre P, Chinetti G, Fruchart JC, Staels B. Sorting out the roles of PPAR\u03b1 in energy metabolism and vascular homeostasis. <i>J. Clin. Invest.<\/i>, <b>116<\/b>, 571\u2013580 (2006).","DOI":"10.1172\/JCI27989"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. PPAR\u03b3 signaling and metabolism: the good, the bad and the future. <i>Nat. Med.<\/i>, <b>19<\/b>, 557\u2013566 (2013).","DOI":"10.1038\/nm.3159"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Dubois V, Eeckhoute J, Lefebvre P, Staels B. Distinct but complementary contributions of PPAR isotypes to energy homeostasis. <i>J. Clin. Invest.<\/i>, <b>127<\/b>, 1202\u20131214 (2017).","DOI":"10.1172\/JCI88894"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Kamata S, Oyama T, Saito K, Honda A, Yamamoto Y, Suda K, Ishikawa R, Itoh T, Watanabe Y, Shibata T, Uchida K, Suematsu M, Ishii I. PPAR\u03b1 ligand-binding domain structures with endogenous fatty acids and fibrates. <i>iScience<\/i>, <b>23<\/b>, 101727 (2020).","DOI":"10.1016\/j.isci.2020.101727"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe RT Jr, McKee DD, Moore JT, Willson TM. Structural determinants of ligand binding selectivity between the peroxisome proliferator-activated receptors. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>98<\/b>, 13919\u201313924 (2001).","DOI":"10.1073\/pnas.241410198"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Cheng HS, Tan WR, Low ZS, Marvalim C, Lee JYH, Tan NS. Exploration and development of PPAR modulators in health and disease: an update of clinical evidence. <i>Int. J. Mol. Sci.<\/i>, <b>20<\/b>, 5055 (2019).","DOI":"10.3390\/ijms20205055"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ. Mechanisms of NAFLD development and therapeutic strategies. <i>Nat. Med.<\/i>, <b>24<\/b>, 908\u2013922 (2018).","DOI":"10.1038\/s41591-018-0104-9"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Agrawal R. The first approved agent in the Glitazar\u2019s Class. Saroglitazar. <i>Curr. Drug Targets<\/i>, <b>15<\/b>, 151\u2013155 (2014).","DOI":"10.2174\/13894501113149990199"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Jani RH, Kansagra K, Jain MR, Patel H. Pharmacokinetics, safety, and tolerability of saroglitazar (ZYH1), a predominantly PPAR\u03b1 agonist with moderate PPAR\u03b3 agonist activity in healthy human subjects. <i>Clin. Drug Investig.<\/i>, <b>33<\/b>, 809\u2013816 (2013).","DOI":"10.1007\/s40261-013-0128-3"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Mitra A. An observational study of reduction in glycemic parameters and liver stiffness by saroglitazar 4\u2009mg in patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease. <i>Cureus<\/i>, <b>12<\/b>, e9065 (2020).","DOI":"10.7759\/cureus.9065"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Roy S. Clinical case series of decrease in shear wave elastography values in ten diabetic dyslipidemia patients having NAFLD with saroglitazar 4\u2009mg: an Indian experience. <i>Case Rep. Med.<\/i>, <b>2020<\/b>, 4287075 (2020).","DOI":"10.1155\/2020\/4287075"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Kaul U, Parmar D, Manjunath K, Shah M, Parmar K, Patil KP, Jaiswal A. New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence. <i>Cardiovasc. Diabetol.<\/i>, <b>18<\/b>, 80 (2019).","DOI":"10.1186\/s12933-019-0884-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kamata S, Oyama T, Ishii I. Preparation of co-crystals of human PPAR\u03b1-LBD and ligand for high-resolution X-ray crystallography. <i>STAR Protoc.<\/i>, <b>2<\/b>, 100364 (2021).","DOI":"10.1016\/j.xpro.2021.100364"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Liu Q, Dahmane T, Zhang Z, Assur Z, Brasch J, Shapiro L, Mancia F, Hendrickson WA. Structures from anomalous diffraction of native biological macromolecules. <i>Science<\/i>, <b>336<\/b>, 1033\u20131037 (2012).","DOI":"10.1126\/science.1218753"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Kabsch W. XDS. <i>Acta Crystallogr. D Biol. Crystallogr.<\/i>, <b>66<\/b>, 125\u2013132 (2010).","DOI":"10.1107\/S0907444909047337"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Evans PR, Murshudov GN. How good are my data and what is the resolution? <i>Acta Crystallogr. D Biol. Crystallogr.<\/i>, <b>69<\/b>, 1204\u20131214 (2013).","DOI":"10.1107\/S0907444913000061"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. <i>J. Appl. Crystallogr.<\/i>, <b>40<\/b>, 658\u2013674 (2007).","DOI":"10.1107\/S0021889807021206"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Emsley P, Cowtan K. Coot: model-building tools for molecular graphics. <i>Acta Crystallogr. D Biol. Crystallogr.<\/i>, <b>60<\/b>, 2126\u20132132 (2004).","DOI":"10.1107\/S0907444904019158"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW, Echols N, Headd JJ, Hung LW, Kapral GJ, Grosse-Kunstleve RW, McCoy AJ, Moriarty NW, Oeffner R, Read RJ, Richardson DC, Richardson JS, Terwilliger TC, Zwart PH. PHENIX: a comprehensive Python-based system for macromolecular structure solution. <i>Acta Crystallogr. D Biol. Crystallogr.<\/i>, <b>66<\/b>, 213\u2013221 (2010).","DOI":"10.1107\/S0907444909052925"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D. Crystal structure of the RAR-\u03b3 ligand-binding domain bound to all-<i>trans<\/i> retinoic acid. <i>Nature<\/i>, <b>378<\/b>, 681\u2013689 (1995).","DOI":"10.1038\/378681a0"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Brown PJ, Stuart LW, Hurley KP, Lewis MC, Winegar DA, Wilson JG, Wilkison WO, Ittoop OR, Willson TM. Identification of a subtype selective human PPAR\u03b1 agonist through parallel-array synthesis. <i>Bioorg. Med. Chem. Lett.<\/i>, <b>11<\/b>, 1225\u20131227 (2001).","DOI":"10.1016\/S0960-894X(01)00188-3"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Brown KK, Henke BR, Blanchard SG, <i>et al.<\/i> A novel <i>N<\/i>-aryl tyrosine activator of peroxisome proliferator-activated receptor-gamma reverses the diabetic phenotype of the Zucker diabetic fatty rat. <i>Diabetes<\/i>, <b>48<\/b>, 1415\u20131424 (1999).","DOI":"10.2337\/diabetes.48.7.1415"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Jang JY, Bae H, Lee YJ, Choi YI, Kim HJ, Park SB, Suh SW, Kim SW, Han BW. Structural basis for the enhanced anti-diabetic efficacy of lobeglitazone on PPAR\u03b3. <i>Sci. Rep.<\/i>, <b>8<\/b>, 31 (2018).","DOI":"10.1038\/s41598-017-18274-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Jiang H, Zhou XE, Shi J, Zhou Z, Zhao G, Zhang X, Sun Y, Suino-Powell K, Ma L, Gao H, Yu X, Li J, Li J, Melcher K, Xu HE, Yi W. Identification and structural insight of an effective PPAR\u03b3 modulator with improved therapeutic index for anti-diabetic drug discovery. <i>Chem. Sci.<\/i>, <b>11<\/b>, 2260\u20132268 (2020).","DOI":"10.1039\/C9SC05487A"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Batista FA, Trivella DB, Bernardes A, Gratieri J, Oliveira PS, Figueira AC, Webb P, Polikarpov I. Structural insights into human peroxisome proliferator activated receptor delta (PPAR-delta) selective ligand binding. <i>PLOS ONE<\/i>, <b>7<\/b>, e33643 (2012).","DOI":"10.1371\/journal.pone.0033643"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Wu CC, Baiga TJ, Downes M, La Clair JJ, Atkins AR, Richard SB, Fan W, Stockley-Noel TA, Bowman ME, Noel JP, Evans RM. Structural basis for specific ligation of the peroxisome proliferator-activated receptor \u03b4. <i>Proc. Natl. Acad. Sci. U.S.A.<\/i>, <b>114<\/b>, E2563\u2013E2570 (2017).","DOI":"10.1073\/pnas.1621513114"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Xu HE, Lambert MH, Montana VG, Parks DJ, Blanchard SG, Brown PJ, Sternbach DD, Lehmann JM, Wisely GB, Willson TM, Kliewer SA, Milburn MV. Molecular recognition of fatty acids by peroxisome proliferator-activated receptors. <i>Mol. Cell<\/i>, <b>3<\/b>, 397\u2013403 (1999).","DOI":"10.1016\/S1097-2765(00)80467-0"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) B\u00e9nardeau A, Benz J, Binggeli A, Blum D, Boehringer M, Grether U, Hilpert H, Kuhn B, M\u00e4rki HP, Meyer M, Puntener K, Raab S, Ruf A, Schlatter D, Mohr P. Aleglitazar, a new, potent, and balanced dual PPAR\u03b1\/\u03b3 agonist for the treatment of type II diabetes. <i>Bioorg. Med. Chem. Lett.<\/i>, <b>19<\/b>, 2468\u20132473 (2009).","DOI":"10.1016\/j.bmcl.2009.03.036"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Cronet P, Petersen JF, Folmer R, Blomberg N, Sjoblom K, Karlsson U, Lindstedt EL, Bamberg K. Structure of the PPAR\u03b1 and -\u03b3 ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. <i>Structure<\/i>, <b>9<\/b>, 699\u2013706 (2001).","DOI":"10.1016\/S0969-2126(01)00634-7"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. <i>J. Med. Chem.<\/i>, <b>43<\/b>, 527\u2013550 (2000).","DOI":"10.1021\/jm990554g"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Dutta D, Bhattacharya S, Surana V, Aggarwal S, Singla R, Khandelwal D, Sharma M. Efficacy and safety of saroglitazar in managing hypertriglyceridemia in type-2 diabetes: A meta-analysis. <i>Diabetes Metab. Syndr.<\/i>, <b>14<\/b>, 1759\u20131768 (2020).","DOI":"10.1016\/j.dsx.2020.08.039"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Krishnappa M, Patil K, Parmar K, Trivedi P, Mody N, Shah C, Faldu K, Maroo S, Parmar D. Effect of saroglitazar 2\u2009mg and 4\u2009mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: a 56-week, randomized, double blind, phase 3 study (PRESS XII study). <i>Cardiovasc. Diabetol.<\/i>, <b>19<\/b>, 93 (2020).","DOI":"10.1186\/s12933-020-01073-w"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Kumar DP, Caffrey R, Marioneaux J, Santhekadur PK, Bhat M, Alonso C, Koduru SV, Philip B, Jain MR, Giri SR, Bedossa P, Sanyal AJ. The PPAR \u03b1\/\u03b3 agonist saroglitazar improves insulin resistance and steatohepatitis in a diet induced animal model of nonalcoholic fatty liver disease. <i>Sci. Rep.<\/i>, <b>10<\/b>, 9330 (2020).","DOI":"10.1038\/s41598-020-66458-z"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Kroker AJ, Bruning JB. Review of the structural and dynamic mechanisms of PPAR\u03b3 partial agonism. <i>PPAR Res.<\/i>, <b>2015<\/b>, 816856 (2015).","DOI":"10.1155\/2015\/816856"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Choi JH, Banks AS, Estall JL, Kajimura S, Bostr\u00f6m P, Laznik D, Ruas JL, Chalmers MJ, Kamenecka TM, Bl\u00fcher M, Griffin PR, Spiegelman BM. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPAR\u03b3 by Cdk5. <i>Nature<\/i>, <b>466<\/b>, 451\u2013456 (2010).","DOI":"10.1038\/nature09291"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Choi JH, Banks AS, Kamenecka TM, Busby SA, Chalmers MJ, Kumar N, Kuruvilla DS, Shin Y, He Y, Bruning JB, Marciano DP, Cameron MD, Laznik D, Jurczak MJ, Sch\u00fcrer SC, Vidovi\u0107 D, Shulman GI, Spiegelman BM, Griffin PR. Antidiabetic actions of a non-agonist PPAR\u03b3 ligand blocking Cdk5-mediated phosphorylation. <i>Nature<\/i>, <b>477<\/b>, 477\u2013481 (2011).","DOI":"10.1038\/nature10383"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Hall JA, Ramachandran D, Roh HC, <i>et al.<\/i> Obesity-linked PPAR\u03b3 S273 phosphorylation promotes insulin resistance through growth differentiation factor 3. <i>Cell Metab.<\/i>, <b>32<\/b>, 665\u2013675.e6 (2020).","DOI":"10.1016\/j.cmet.2020.08.016"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/9\/44_b21-00232\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T04:20:35Z","timestamp":1630729235000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/44\/9\/44_b21-00232\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":38,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b21-00232","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,1]]},"article-number":"b21-00232"}}